Menopause International > Volume 14, Number 2 > Pp. 57-62

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Samat, A. Articles by Barnett, A. Search for Related Content PubMed PubMed Citation Social Bookmarking                      What's this?

Review

Pharmacotherapy for obesity in menopausal women

Ashish Samat , Asad Rahim and Anthony Barnett

Department of Diabetes and Endocrinology, Birmingham Heartlands Hospital, Birmingham, UK

Correspondence: Ashish Samat, Department of Diabetes and Endocrinology, Birmingham Heartlands Hospital, Birmingham, UK. Email: ashishsamat{at}hotmail.com
Weight gain, during and after the menopause is common. Contributing factors include ethnicity, reduced physical activity, reduced lean mass, reduced resting metabolic rate and treatment with certain drugs, e.g. steroids, insulin, glitazones. Excess body weight increases the risk of medical conditions including type 2 diabetes, hypertension, osteoarthritis, certain cancers and is associated with increased mortality. This review examines pharmacological approaches to promote weight loss. Pharmacological therapy should be considered as an adjunct to diet and lifestyle changes. The licensed drugs orlistat, sibutramine and rimonabant are discussed. Obesity increases the risk of type 2 diabetes. Thus, the effects of metformin and exenatide are examined.

Key Words: Bariatric surgery • obesity • orlistat • rimonabant sibutramine

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?